Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review
Current Oncology · 14.04.2026 · 33 (4) · 214
DOI: 10.3390/curroncol33040214 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, online erschienen am 14.04.2026. Verfasst von Qian Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Chin…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Afatinib, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR)-kinase domain duplication (KDD) represents an atypical mutation distinct from classical EGFR mutations in lung adenocarcinoma (LUAD). Although first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated clinical activity in EGFR-KDD, the mechanisms of acquired resistance in this setting remain poorly characterized. Herein, we present a LUAD patient with EGFR-KDD who achieved a sustained initial response to afatinib lasting 67 months before developing acquired resistance. Re-biopsy with next-generation sequencing (NGS) uncovered EGFR T790M, accompanied by EGFR amplification and EGFR M766T. The patient was switched to firmonertinib, with subsequent tumor regression. We reviewed published EGFR-KDD cases that had both acquired resistance to first- or second-generation EGFR-TKIs and corresponding repeat biopsy findings. Five of the eleven cases harbored EGFR T790M, yielding a prevalence of 45%, which is similar to that seen in classical EGFR mutations. This case suggests that EGFR T790M mediates acquired resistance to first- and second-generation EGFR-TKIs in EGFR-KDD, mirroring the resistance pattern observed in classical EGFR mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Zitieren
APA
Liu, Q., Lv, L., Pang, G., & Wang, P. (2026). Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review. Current Oncology, 33(4), 214. https://doi.org/10.3390/curroncol33040214
Vancouver
Liu Q, Lv L, Pang G, Wang P. Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review. Current Oncology. 2026;33(4):214. doi:10.3390/curroncol33040214
BibTeX
@article{Liu2026,
author = {Liu, Qian and Lv, Lu and Pang, Guanchao and Wang, Pingli},
title = {Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {4},
pages = {214},
doi = {10.3390/curroncol33040214}
}
EUVIMED